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Abstract
Background:  Diffuse alveolar haemorrhage (DAH) is a serious pulmonary complication
characterised by a high mortality rate and the absence of specific treatment. The intrapulmonary
administration of activated recombinant factor VII (rFVIIa) in DAH was recently published in six
patients by Heslet et al with an efficient hemostatic effect. We describe two cases of DAH treated
with intrapulmonary rFVIIa.
Methods: Two cases of DAH were admitted to the ICU after presenting abrupt desaturation,
tachypnea, cough and haemoptysis, requiring orotracheal intubation and mechanical ventilation.
The diagnosis was achieved by the bloody return during the bronchoalveolar lavage, during the
procedure rFVIIa (50 μg/Kg in 50 ml of isotonic saline) was administered via the bronchoscope.
Results: Immediate cessation of bleeding was observed. Prior to intrapulmonary administration of
rFVIIa, the FiO2 was 1, which was reduced to 0.4 24 hours later. Following the procedure, the
haemostatic effect made blood transfusion superfluous. No thrombotic complications associated
with administration of the drug were observed. After the intervention both cases progressed fast
and was discharged from the ICU with no further episodes of bleeding.
Conclusion: 1. Local intrabronchial deposition of DAH with rFVIIa has been shown to be effective
in controlling life-threatening DAH. 2. In the case described above, no thrombotic complications
were observed following the intrapulmonary administration of rFVIIa.
Background
Diffuse alveolar haemorrhage (DAH) is a serious pulmo-
nary complication, characterised by the presence of hae-
moptysis, dyspnea, hypoxemia and anaemia, with a high
mortality rate of over 50% of patients requiring mechani-
cal ventilation [1]. Diffuse opacities found on X rays in
patients with DAH, however, are unspecific [2].
DAH is a complication of systemic diseases, and fre-
quently manifests as an initial sign of these [3]. Broncho-
alveolar lavage (BAL) is the most useful procedure for
confirming initial clinical suspicion, BAL with a bloody
return is the only way to confirm the diagnosis and, at
times, fiberoptic bronchoscopy provides the treatment. In
a new development, its use in intrapulmonary administra-
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tion of recombinant activated factor VII (rFVIIa) has been
reported in six patients [4].
The drug (rFVIIa) promotes local formation of thrombin
when it combines with tissue factor exposed at the level of
the endothelium. It was initially indicated to treat coagu-
lopathies in patients suffering from haemophilia,
although its use has extended to other haematological
conditions. Beyond these indications, it is administrated
on a more compassionate level. The requirements for its
effective use in controlling serious haemorrhages are
fibrinogen and platelet readings of over a 50 mg/dl and
with 50.000/μl respectively, in addition to a pH > 7.20.
We present two cases of massive haemoptysis in which
local administration of rFVIIa (Novoseven®  from
Novonordisk) via BAL was used as an emergency measure.
Case presentation
Two cases of life-threatening DAH were admitted to the
ICU after presenting abrupt desaturation, tachypnea,
cough and haemoptysis, requiring orotracheal intubation
and mechanical ventilation. Both cases were diagnosed
with fiberoptic bronchoscopy and treated with local
rFVIIa.
Clinical case 1
A 39 year old woman, with a personal history of acute pro-
myelocytic leukaemia treated with chemotherapy and
renal failure with recent arteriovenous fistula interven-
tion. The patient was admitted to the ICU with hypoxemic
respiratory failure with cough and haemoptysis, requiring
orotracheal intubation and mechanical ventilation. The
thorax X-ray showed a "patchy" infiltrate affecting bases
and middle fields. Values of haemoglobin with 11,4
decreased to 7,9 g/dl concomitant with reduced platelet
count from 100 × 10[3]/μL to 40 × 10[3]/μL during the
first 24 hours. Suddenly, the patient deteriorated with an
abrupt desaturation and frank haemoptysis through the
orotracheal tube. In order to achieve platelet readings of
over 50,000/μL a transfusion of 8 units of platelets was
necessary before the drug could be administered. An
emergency fibrobronchoscopy confirmed DAH. Systemic
administration of rFVIIa was considered, but the potential
thrombogenic effect of the drug and the risk of obstruc-
tion of the recent arteriovenous fistula prompted us to
decide to administer 50 μg/Kg of rFVIIa in 50 ml of isot-
onic saline via the bronchoscopy channel, 25 ml in each
main bronchus; following this, immediate cessation of
bleeding was observed. Prior to this, the families had been
informed and their written consent obtained.
The inspired fraction of oxygen (FiO2) which, before
intrapulmonary administration of rFVIIa had been 1, was
reduced to 0.6 during the first three hours subsequent to
the administration of rFVIIa, and to 0.4 over the following
24 hours (figure 1). Haemoglobin readings remained
unchanged without the need for blood transfusion.
Although there were no new episodes of active DAH,
weaning from ventilator was retarded due to muscular
weakness. The patient was extubated at day 16 in the ICU
and discharged to stationary ward without recurrent
bleeding.
Changes in the FiO2 following rFVIIa administration in two cases treated with intrapulmonary rFVIIa Figure 1
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Clinical case 2
A 46 year old man, with a personal history of smoking, ex
parenteral drug abuse, hepatitis B and C infection, hepatic
cirrhosis evolving for years and HIV infection diagnosed
in 1988; currently receiving antiretroviral treatment. He
was admitted to the ICU with acute inferoposterior myo-
cardial infarction. Treatment was commenced with low
molecular weight heparin and double anti-aggregation
therapy with aspirin and clopidogrel. After 24 hours, he
suddenly developed haemoptysis, acute hypoxemic respi-
ratory failure and bilateral crackles, requiring orotracheal
intubation and mechanical ventilation with FiO2 of 1 to
maintain a SpO2 of 85–90%. The BAL return was increas-
ingly bloody from both lungs. Due to the potential
thrombogenic effect of systemic rFVIIa administration in
acute myocardial infarction, and after informing and
obtaining consent from the family, we decided on
intrapulmonary administration of the drug at a dosage of
50 μg/Kg in 50 ml of isotonic saline via the bronchoscopy
channel, observing the immediate cessation of bleeding.
The FiO2 was reduced to 0.5 over the first three hours and
to 0.35 after 24 hours (figure 1). After 12 days on mechan-
ical ventilation the patient was extubated and transferred
to a stationary ward.
Discussion
Systemic administration of rFVIIa to patients with life-
threatening conditions due to active haemorrhage has
increased in clinical practise, based more on presumed
expectation than on scientific evidence supported by con-
trolled and randomised studies [5].
Edward et al carried out a survey in the American College
of Chest Physicians (ACCP) in 1998 on the treatment of
acute haemoptysis: 85% of specialists answered that intu-
bation and connection to mechanical ventilation must be
performed at an early stage and 64% considered it manda-
tory to carry out a fibrobronchoscopy during the first 24
hours [6]. Consequently, treatment undertaken in both
clinical cases presented – mechanical ventilation support
and fibrobronchoscopy – meets these recommendations
and was performed as an emergency measure to treat a
massive haemoptysis episode. In middle-sized hospital,
where selective embolization of the bronchial artery tech-
niques and/or thoracic surgery are not available, systemic
rFVIIa has been used in massive haemoptysis cases, with
good results [7].
DAH in haematological patients requiring mechanical
ventilation has a high mortality rate of over 70% in series
described [8,9]. This is due to the absence of specific treat-
ment for DAH of haematological origin. The results of a
multicentre, randomised study on the efficacy and safety
of three different dosages of systemic rFVIIa compared
with a placebo in treating haemorrhagic complications in
100 bone-marrow transplant patients (seven with DAH)
were inconclusive, 8% of thromboembolic events were
observed in the group treated with rFVIIa [10].
Pulmonary haemorrhage associated with myocardial inf-
arction thrombolysis is an unusual complication; in 1996,
Chang YC et al published a retrospective study, finding an
incidence of 0.4% [11]. The same is true of platelet antiag-
gregation treatment, where isolated cases of DAH have
been described [12]. In spite of its low incidence, DAH
secondary to acute coronary syndrome treatment is a com-
plication which maybe undetected, due to the common
radiological findings in both DAH and ALI/ARDS and
acute pulmonary oedema [13]. Bearing in mind the
thrombogenic risk of a systemic administration of local
rFVIIa, and with Heslet et al's publication as a reference,
in which 6 consecutive critically ill patients with acute
DAH are treated with local rFVIIa, intrapulmonary admin-
istration of the drug was chosen in the cases here pre-
sented with a view to avoiding the risk of thrombosis of
the arteriovenous fistula in the first case, and of reinfarc-
tion in the second [4,10].
Conclusion
DAH is a life-threatening disease characterised by the lack
of specific treatment and a high mortality of patients
requiring mechanical ventilation. Bronchoscopy BAL with
increasingly bloody return is the only diagnostic proce-
dure for the diagnosis of DAH, and at times, provides the
treatment. Local administration of rFVIIa via the fibro-
bronchoscope channel was used as an emergency measure
in two cases of massive haemoptysis with an excellent
hemostatic effect and without adverse effects.
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